Cargando…
Inflammatory predictors (eosinophil, C-RP and IL-6) and effectiveness of oral Azvudine tablets treatment in COVID-19 hospitalized patients: A retrospective, self-controlled study
BACKGROUND: Although vaccinations and antiviral drugs are widely used in the clinical treatment worldwide, there is little investigation on the clinical outcomes and effectiveness of oral Azvudine tablets (FNC) treatment in COVID-19 hospitalized patients. The previous data showed Azvudine treatment...
Autores principales: | Zhao, Yanli, Gao, Gan, Li, Wenhui, Xu, Zuqing, Wang, Xiao, Chang, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682612/ https://www.ncbi.nlm.nih.gov/pubmed/38034620 http://dx.doi.org/10.1016/j.heliyon.2023.e21941 |
Ejemplares similares
-
The first Chinese oral anti-COVID-19 drug Azvudine launched
por: Yu, Bin, et al.
Publicado: (2022) -
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023) -
Azvudine reduces the in-hospital mortality of COVID-19 patients: A retrospective cohort study
por: Zong, Kaican, et al.
Publicado: (2023) -
A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study
por: Ren, Zhigang, et al.
Publicado: (2020) -
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
por: Dian, Yating, et al.
Publicado: (2023)